US 9,810,701 B2
Analysis of direct factor Xa inhibitors
Job Harenberg, Heidelberg (DE); and Roland Krämer, Münster (DE)
Assigned to Doasense GmbH, Heidelberg (DE)
Filed by DOASENSE GMBH, Heidelberg (DE)
Filed on Aug. 11, 2015, as Appl. No. 14/823,472.
Application 14/823,472 is a division of application No. 13/885,725, granted, now 9,133,501, previously published as PCT/EP2011/005586, filed on Nov. 7, 2011.
Claims priority of application No. 1019674.9 (GB), filed on Nov. 22, 2010.
Prior Publication US 2016/0011218 A1, Jan. 14, 2016
Int. Cl. G01N 33/86 (2006.01); G01N 33/58 (2006.01); C12Q 1/56 (2006.01)
CPC G01N 33/86 (2013.01) [C12Q 1/56 (2013.01); G01N 33/58 (2013.01); G01N 2333/811 (2013.01); G01N 2333/96444 (2013.01); G01N 2458/30 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A diagnostic kit for monitoring the course of treatment with factor Xa inhibitors in a patient comprising a composition containing factor Xa and composition containing a chromogenic substrate conjugated to a detectable substance, wherein the chromogenic substrate conjugated to the detectable substance is selected from the group consisting of N-Benzoyl-Ile-Glu-Gly-Arg p-nitroanilide acetate salt (SEQ ID NO:04), N-benzoyl-L-isoleucyl-L-glutamyl-L-glycyl-L-arginine-para-nitroaniline hydrochloride (SEQ ID NO:01), Boc-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin hydrochloride (SEQ ID NO:05), and 4-Nitrophenyl 4-guanidinobenzoate hydrochloride, and wherein the composition containing the factor Xa and/or the composition containing the chromogenic substrate conjugated to the detectable substance are immobilized on a test strip.